Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Langdon

Showing results (151-160 of 180) with videos related to

Pageof 18
Sort By:
Exploration of Targeted Anti-Tumor Therapy|April 20, 2022
Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer modelKate M Moore, Vera Cerqueira, Kenneth G MacLeod, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 7, 2000
A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissuesJ Pan, E J Kunkel, U Gosslar, et al.
Cancer Research|August 6, 2009
Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinomaWataru Sakai, Elizabeth M Swisher, Céline Jacquemont, et al.
British Journal of Cancer|August 1, 1992
Growth control by epidermal growth factor and transforming growth factor-alpha in human lung squamous carcinoma cellsG J Rabiasz, S P Langdon, J M Bartlett, et al.
British Journal of Cancer|August 1, 1990
Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell linesS P Langdon, M M Hawkes, S S Lawrie, et al.
BMC Cancer|June 6, 2018
Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatmentChrysi Xintaropoulou, Carol Ward, Alan Wise, et al.
International Journal of Cancer|September 30, 1993
Contrasting effects of 17 beta-estradiol on the growth of human ovarian carcinoma cells in vitro and in vivoS P Langdon, A Ritchie, K Young, et al.
Cancer Research|November 15, 1987
Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazineM F Stevens, J A Hickman, S P Langdon, et al.
European Journal of Medicinal Chemistry|August 17, 2019
Carbonic anhydrase inhibitors based on sorafenib scaffold: Design, synthesis, crystallographic investigation and effects on primary breast cancer cellsMurat Bozdag, Marta Ferraroni, Carol Ward, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 1998
Functionality of the progesterone receptor in ovarian cancer and its regulation by estrogenS P Langdon, H Gabra, J M Bartlett, et al.
Pageof 18

Showing results (151-160 of 180) with videos related to

Sort By:
Pageof 18
Exploration of Targeted Anti-Tumor Therapy|April 20, 2022
Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer modelKate M Moore, Vera Cerqueira, Kenneth G MacLeod, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 7, 2000
A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissuesJ Pan, E J Kunkel, U Gosslar, et al.
Cancer Research|August 6, 2009
Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinomaWataru Sakai, Elizabeth M Swisher, Céline Jacquemont, et al.
British Journal of Cancer|August 1, 1992
Growth control by epidermal growth factor and transforming growth factor-alpha in human lung squamous carcinoma cellsG J Rabiasz, S P Langdon, J M Bartlett, et al.
British Journal of Cancer|August 1, 1990
Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell linesS P Langdon, M M Hawkes, S S Lawrie, et al.
BMC Cancer|June 6, 2018
Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatmentChrysi Xintaropoulou, Carol Ward, Alan Wise, et al.
International Journal of Cancer|September 30, 1993
Contrasting effects of 17 beta-estradiol on the growth of human ovarian carcinoma cells in vitro and in vivoS P Langdon, A Ritchie, K Young, et al.
Cancer Research|November 15, 1987
Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazineM F Stevens, J A Hickman, S P Langdon, et al.
European Journal of Medicinal Chemistry|August 17, 2019
Carbonic anhydrase inhibitors based on sorafenib scaffold: Design, synthesis, crystallographic investigation and effects on primary breast cancer cellsMurat Bozdag, Marta Ferraroni, Carol Ward, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 1998
Functionality of the progesterone receptor in ovarian cancer and its regulation by estrogenS P Langdon, H Gabra, J M Bartlett, et al.
Pageof 18